Zymeworks (ZYME) Earnings Date & Reports

Key Takeaways

• Zymeworks is set to report second-quarter 2026 financial results on Thursday, August 6, after the market close — without hosting a conference call.
• Wall Street consensus points to an earnings per share (EPS) of approximately -$0.42 on revenue near $18.1 million, reflecting continued milestone-dependent revenue patterns.
• The proposed $929 million acquisition of Theravance Biopharma and its financing structure are expected to dominate investor attention in the absence of a management Q&A session.
• A U.S. PDUFA (Prescription Drug User Fee Act) decision date for Ziihera (zanidatamab-hrii) is scheduled for August 25, 2026, only 19 days after earnings, making pipeline commentary a focal point.
• Q1 2026 results missed consensus estimates by a wide margin, with EPS of -$0.59 versus an expected -$0.10 — raising the stakes for the upcoming report.

Earnings Context and Why It Matters

Zymeworks Inc. enters its second-quarter 2026 earnings report at a pivotal strategic inflection point. The biotechnology company is transitioning from a pure-play oncology drug developer into a hybrid model that combines internal pipeline advancement with royalty-generating commercial assets. The recently announced acquisition of Theravance Biopharma — valued at approximately $929 million and funded through a mix of acquired cash, non-recourse royalty financing from OMERS Life Sciences, and corporate capital — represents the first concrete execution of a strategy management unveiled in late 2025. With no post-earnings conference call scheduled, investors will have limited opportunity to probe management on integration timelines, cost synergies, or pipeline updates, making the written earnings release and any forward-looking commentary especially consequential.

Earnings Expectations

Consensus estimates for Zymeworks' second quarter of 2026, as compiled by Yahoo Finance from nine analysts, project an EPS of -$0.42 on average, with individual estimates ranging from -$0.61 to $0.03. The average revenue estimate stands at approximately $18.1 million, though the wide spread between the low estimate of $1.21 million and the high estimate of $45 million underscores the inherent difficulty in modeling Zymeworks' milestone-driven top line. For context, the company reported revenue of $48.73 million in the same quarter a year ago (Q2 2025), alongside a positive EPS of $0.03 — both of which benefited from significant partner milestone payments.

Last quarter, Zymeworks posted Q1 2026 revenue of just $2.41 million, down 91.1% year-over-year and well below the $24.38 million consensus, while EPS came in at -$0.59 against an expected -$0.10. The steep sequential and year-over-year declines highlight the lumpy nature of the company's revenue recognition, which depends heavily on the timing of milestone achievements from partners including Jazz Pharmaceuticals and BeOne Medicines (formerly BeiGene). Investors will closely monitor whether Q2 benefited from any milestone payments recognized during the period, as well as the updated cash position — which stood at $403.8 million as of March 31, 2026.

AI Screener

For investors looking to stay ahead of earnings-driven moves in the biotechnology sector, Tickeron's AI Screener offers a powerful way to filter and discover stocks based on technical patterns, fundamental metrics, and AI-driven trading signals. The platform enables users to scan thousands of stocks and exchange-traded funds (ETFs) using customizable criteria such as industry classification, market capitalization, volatility levels, and price pattern recognition — helping traders identify breakout candidates, emerging trends, and actionable trade ideas far more efficiently than manual screening. Whether monitoring pre-earnings setups or post-report momentum, the AI Screener can help streamline the research process. Explore how it can support your market analysis by visiting the AI Screener today.

Market Reaction and Investor Sentiment

Investor sentiment heading into Zymeworks' Q2 2026 report appears cautiously optimistic but layered with uncertainty. The stock has drawn a "Strong Buy" consensus from analysts, with price targets ranging from $28 to $58 and an average near $39, according to recent data. Truist lifted its target to $31 in early July, while Wells Fargo raised its target to $37, both citing the strategic logic of the Theravance acquisition. However, the company's decision to forgo a traditional earnings conference call removes a key channel for addressing investor questions around integration execution, cost synergy realization, and pipeline timelines. Additionally, the Q1 earnings miss — where EPS fell nearly 500% below consensus — remains fresh in memory, and another significant deviation could test the market's patience. The upcoming PDUFA date for Ziihera on August 25 adds an asymmetric catalyst that could overshadow the quarterly financials if the FDA decision proves favorable.

Forward Outlook and Key Factors to Monitor

Looking beyond the Q2 print, several interconnected factors will shape Zymeworks' trajectory through the remainder of 2026 and into 2027.

The most immediate catalyst is the August 25 PDUFA date for Ziihera in first-line gastroesophageal adenocarcinoma (GEA). An approval would trigger a $250 million milestone payment from Jazz Pharmaceuticals and unlock a royalty revenue stream that management expects to meaningfully extend the company's cash runway — already projected beyond 2028 when including anticipated regulatory milestones totaling approximately $440 million across the U.S., Europe, Japan, and China.

The Theravance Biopharma acquisition, expected to close in the second half of 2026, will add YUPELRI — a once-daily nebulized long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD) maintenance — to Zymeworks' portfolio. YUPELRI contributes approximately $60 million in annual cash flows, with patent protection extending to 2039. Investors should monitor closing timelines, integration progress, and any updates on the GSK-partnered Trelegy royalty stream, which could contribute a $100 million milestone payment in early 2027.

On the pipeline front, the ZW191 folate receptor alpha-targeted antibody-drug conjugate (ADC) continues to generate encouraging Phase 1 data in platinum-resistant ovarian and endometrial cancers, with confirmed objective response rates (ORR) reaching 61% at optimized dose levels. Meanwhile, the company's pan-RAS ADC preclinical program and the ZW1528 IND (Investigational New Drug) filing — now guided to 2027 — represent longer-duration value drivers. The absence of a conference call means investors will need to rely on the earnings press release and subsequent regulatory or medical meeting updates to gauge progress across these programs. Cash burn, operating expense discipline, and share repurchase activity under the $125 million buyback program also remain important quantitative signals to track.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations